Abstract
Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.
Keywords: Carotid stenosis, cerebral hemorrhage, cholesterol, risk, statins, stroke, therapy, treatment.
Current Vascular Pharmacology
Title:Risk and Benefit of Statins in Stroke Secondary Prevention
Volume: 11 Issue: 6
Author(s): Patrice Laloux
Affiliation:
Keywords: Carotid stenosis, cerebral hemorrhage, cholesterol, risk, statins, stroke, therapy, treatment.
Abstract: Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.
Export Options
About this article
Cite this article as:
Laloux Patrice, Risk and Benefit of Statins in Stroke Secondary Prevention, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/157016111106140128113121
DOI https://dx.doi.org/10.2174/157016111106140128113121 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Discharge Interventions and Modifiable Risk Factors for Preventing Hospital Readmissions in Children with Medical Complexity
Reviews on Recent Clinical Trials New Treatments for COPD in the Elderly
Current Pharmaceutical Design Mst1: Function and Mechanism in Brain and Myocardial Ischemia Reperfusion Injury
Current Neuropharmacology Cigarette Smoking in Methadone Maintained Patients: An Up-to-Date Review
Current Drug Abuse Reviews Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Natural Compounds with Cell Growth Inhibitory Activity in Human Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Crystal Structure and Biological Evaluation of 4, 5, 6, 7-tetrahydropravastatin as HMG-CoA Reductase Inhibitor
Letters in Drug Design & Discovery Iron-Induced Fibrin in Cardiovascular Disease
Current Neurovascular Research Magnesium and Anaesthesia
Current Drug Targets Sonic Hedgehog Signaling Activation Promotes Cardioprotective Strategies
Current Signal Transduction Therapy Clinical Utility of Acarbose, an α-Glucosidase Inhibitor in Cardiometabolic Disorders
Current Drug Metabolism Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Editorial (Thematic Issue: Biomarkers of Impaired Innate and Adaptive Immunity in Health and Disease)
Current Immunology Reviews (Discontinued) Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence
Current Drug Targets - Cardiovascular & Hematological Disorders